Genome Editing Composition With Cas-CLOVER for Precise Targeted Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genome editing technologies suffer from limitations such as random insertion locations, low precision, and safety concerns in applications like regenerative medicine and immuno-oncology, necessitating the development of more efficient and targeted gene editing platforms.
Innovation Solution
The use of a polypeptide with the amino acid sequence of SEQ ID NO: 35, combined with a guide RNA, encapsulated in lipid nanoparticles, enhances genome editing efficiency by achieving targeted modifications with higher yields and improved safety, particularly through the use of mutant Cas-CLOVER enzymes with specific amino acid modifications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional genome editing strategies are used, then targeted modification of specific DNA areas is achieved, but the precision and reproducibility are limited compared to earlier technologies
Solution Approach 1:
The patent modifies the Cas9 protein by introducing specific amino acid mutations (D10A and H840A) to create a nuclease-inactivated variant (dCas9) that binds DNA but cannot cleave it. This parameter change in the protein's catalytic activity enables precise targeting and stabilization of DNA complexes for editing, improving both precision and reproducibility of genome modification.
Solution Approach 2:
The invention uses composite protein structures by fusing dCas9 with other functional domains (such as transcriptional activators, repressors, or epigenetic modifiers) to create multipurpose editing platforms. This composite approach enables precise control over genome modification outcomes while improving reproducibility through standardized fusion protein systems.
2Productivity
If Cas-CLOVER enzymes with specific amino acid modifications are used, then higher rates of targeted genome modifications are achieved, but the complexity of the editing platform increases
Solution Approach 1:
The patent divides the genome editing function into separate modular components: the dCas9 protein module (with specific amino acid mutations D10A and H840A), the guide RNA module (for target recognition), and the effector module (for genetic modification). This segmentation allows each component to be optimized independently, increasing the rate of targeted modifications while managing platform complexity through standardization.
Solution Approach 2:
By introducing specific amino acid mutations (D10A and H840A) in the dCas9 protein, the invention changes the enzyme's parameters to achieve higher modification rates. These targeted mutations optimize the protein's binding affinity and stability without requiring complete redesign of the entire editing platform, thus improving productivity while controlling complexity.
3Productivity
If higher yields of modified cells are achieved, then therapeutic efficacy is improved, but unintended effects and safety concerns increase
Solution Approach 1:
The dCas9 protein acts as an intermediary that binds to target DNA sequences and stabilizes complexes that recruit therapeutic effectors, such as base editors or prime editors. This intermediary function enables precise control over where and how modifications occur, increasing the yield of desired modified cells while minimizing unintended effects through spatial and temporal control of the editing process.
Solution Approach 2:
The invention incorporates feedback mechanisms through guide RNA design and dCas9 mutation optimization to monitor and control editing outcomes. The specific amino acid mutations in dCas9 (D10A and H840A) enable controlled binding that can be regulated by cellular conditions, providing feedback control to prevent off-target effects while maintaining high yields of correctly modified cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in higher rates of targeted genome modifications, enabling effective therapeutic applications by increasing the therapeutic index of efficacy, reducing unintended effects, and facilitating the development of safe donor cells for cell therapy treatments.
Implementation Method 1
at least one guide RNA (gRNA)
Implementation Method 2
the composition is encapsulated in at least one lipid nanoparticle
Data Source
AI summary
Disclosed are methods and compositions for functional genetic modifications at selected sites. Also provided are cell populations, which comprise targeted integration of one or more exogenous polynucleotides, and/or indels at one or more selected gene loci.